The SYSCID map: a graphical and computational resource of molecular mechanisms across rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease
[en] Chronic inflammatory diseases (CIDs), including inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are thought to emerge from an impaired complex network of inter- and intracellular biochemical interactions among several proteins and small chemical compounds under strong influence of genetic and environmental factors. CIDs are characterised by shared and disease-specific processes, which is reflected by partially overlapping genetic risk maps and pathogenic cells (e.g., T cells). Their pathogenesis involves a plethora of intracellular pathways. The translation of the research findings on CIDs molecular mechanisms into effective treatments is challenging and may explain the low remission rates despite modern targeted therapies. Modelling CID-related causal interactions as networks allows us to tackle the complexity at a systems level and improve our understanding of the interplay of key pathways. Here we report the construction, description, and initial applications of the SYSCID map (<jats:ext-link>https://syscid.elixir-luxembourg.org/</jats:ext-link>), a mechanistic causal interaction network covering the molecular crosstalk between IBD, RA and SLE. We demonstrate that the map serves as an interactive, graphical review of IBD, RA and SLE molecular mechanisms, and helps to understand the complexity of omics data. Examples of such application are illustrated using transcriptome data from time-series gene expression profiles following anti-TNF treatment and data from genome-wide associations studies that enable us to suggest potential effects to altered pathways and propose possible mechanistic biomarkers of treatment response.
Disciplines :
Genetics & genetic processes
Author, co-author :
Acencio, Marcio Luis
Ostaszewski, Marek
Mazein, Alexander
Rosenstiel, Philip
Aden, Konrad
Mishra, Neha
Andersen, Vibeke
Sidiropoulos, Prodromos
Banos, Aggelos
Filia, Anastasia
Rahmouni, Souad ; Université de Liège - ULiège > GIGA > GIGA Medical Genomics - Unit of Animal Genomics
The SYSCID map: a graphical and computational resource of molecular mechanisms across rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease
El-Gabalawy H Guenther LC Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl (2010) 85:2–10. doi: 10.3899/jrheum.091461
Jairath V Feagan BG. Global burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol (2020) 5(1):2–35. doi: 10.1016/S2468-1253(19)30358-9
Jacobs P Bissonnette R Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases–focusing on work productivity and disability. J Rheumatol Supplement (2011) 88(November):55–61. doi: 10.3899/jrheum.110901
Jung SM Kim W-U. Targeted immunotherapy for autoimmune disease. Immune Network (2022) 22(1):e95. doi: 10.4110/in.2022.22.e9
Maniadakis N Toth E Schiff M Wang X Nassim M Szegvari B et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv Ther (2018) 35(9):1333–555. doi: 10.1007/s12325-018-0759-0
Nikolaus S Raedler A Kühbacher T Sfikas N Fölsch UR Schreiber S. Mechanisms in failure of infliximab for crohn’s disease. Lancet (2000) 356(9240):1475–79. doi: 10.1016/S0140-6736(00)02871-3
Ordás I Feagan BG Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 10(10):1079–875. doi: 10.1016/j.cgh.2012.06.032
D’Antiga L. Coronaviruses and immunosuppressed patients: The facts during the third epidemic. Liver Transpl (2020) 26(6):832–4. doi: 10.1002/lt.25756
Sim TM Ong SJ Mak A Tay SH. Type I interferons in systemic lupus erythematosus: A journey from bench to bedside. Int J Mol Sci (2022) 23(5):25055. doi: 10.3390/ijms23052505
Yang B Zhao M Wu H Lu Q. A comprehensive review of biological agents for lupus: beyond single target. Front Immunol (2020) 11:539797(October). doi: 10.3389/fimmu.2020.539797
Gold SL Steinlauf AF. Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: A review of the literature. Gastroenterol Hepatol (2021) 17(9):406–145.
Robinson WH Lindstrom TM Cheung RK Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol (2013) 9(5):267–765. doi: 10.1038/nrrheum.2013.14
Funahashi A Morohashi M Kitano H Tanimura N. CellDesigner: A process diagram editor for gene-regulatory and biochemical networks. BIOSILICO (2003) 1(5):159–625. doi: 10.1016/S1478-5382(03)02370-9
Le Novère N Hucka M Mi H Moodie S Schreiber F Sorokin A et al. The systems biology graphical notation. Nat Biotechnol (2009) 27(8):735–41. doi: 10.1038/nbt.1558
Gawron P Ostaszewski M Satagopam V Gebel S Mazein A Kuzma M et al. MINERVA—a platform for visualization and curation of molecular interaction networks. NPJ Syst Biol Appl (2016) 2(1):16020. doi: 10.1038/npjsba.2016.20
Mazein A Acencio ML Balaur I Rougny A Welter D Niarakis A et al. A guide for developing comprehensive systems biology maps of disease mechanisms: planning, construction and maintenance. Front Bioinform (2023) 3:1197310. doi: 10.3389/fbinf.2023.1197310
Novère NLe Finney A Hucka M Bhalla US Campagne F Collado-Vides J et al. Minimum information requested in the annotation of biochemical models (MIRIAM). Nat Biotechnol (2005) 23(12):1509–15. doi: 10.1038/nbt1156
Ashburner M Ball CA Blake JA Botstein D Butler H Cherry JM et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet (2000) 25(1):25–9. doi: 10.1038/75556
Gene Ontology Consortium. The gene ontology resource: enriching a GOld mine. Nucleic Acids Res (2021) 49(D1):D325–34. doi: 10.1093/nar/gkaa1113
Hastings J Owen G Dekker A Ennis M Kale N Muthukrishnan V et al. ChEBI in 2016: improved services and an expanding collection of metabolites. Nucleic Acids Res (2016) 44(D1):D1214–9. doi: 10.1093/nar/gkv1031
Wishart DS Feunang YD Guo A Lo EJ Marcu A Grant JR et al. DrugBank 5.0: A major update to the drugBank database for 2018. Nucleic Acids Res (2018) 46(D1):D1074–82. doi: 10.1093/nar/gkx1037
Buniello A MacArthur JAL Cerezo M Laura W Hayhurst J et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res (2019) 47(D1):D1005–12. doi: 10.1093/nar/gky1120
Dhamija S Menon MB. Non-coding transcript variants of protein-coding genes - what are they good for? RNA Biol (2018) 15(8):1025–315. doi: 10.1080/15476286.2018.1511675
Mishra N Aden K Blase JI Baran N Bordoni D Tran F et al. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease. Genome Med (2022) 14(1):110. doi: 10.1186/s13073-022-01112-z
Hoksza D Gawron P Ostaszewski M Smula E Schneider R. MINERVA API and plugins: opening molecular network analysis and visualization to the community. Bioinf (Oxford England) (2019) 35(21):4496–985. doi: 10.1093/bioinformatics/btz286
Dainichi T Kabashima K Ivanov II Goto Y. Editorial: regulation of immunity by non-immune cells. Front Immunol (2021) 12:770847(September). doi: 10.3389/fimmu.2021.770847
Yoshitomi H. Regulation of immune responses and chronic inflammation by fibroblast-like synoviocytes. Front Immunol (2019) 10:1395. doi: 10.3389/fimmu.2019.01395
Carrión M Juarranz Y Martínez C González-Álvaro I Pablos JoséL Gutiérrez-Cañas I et al. IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatol (Oxford England) (2013) 52(12):2177–865. doi: 10.1093/rheumatology/ket315
Brentano F Schorr O Ospelt C Stanczyk J Gay RE Gay S et al. Pre-B cell colony-Enhancing factor/Visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-Degrading activities. Arthritis Rheumatism (2007) 56(9):2829–395. doi: 10.1002/art.22833
Kusunoki N Kitahara K Kojima F Tanaka N Kaneko K Endo H et al. Adiponectin stimulates prostaglandin E(2) production in rheumatoid arthritis synovial fibroblasts. Arthritis Rheumatism (2010) 62(6):1641–495. doi: 10.1002/art.27450
Rengel Y Ospelt C Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther (2007) 9(5):2215. doi: 10.1186/ar2304
Geven EJW Bosch MHJv Ceglie IDi Ascone G Abdollahi-Roodsaz S Sloetjes AW et al. S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis. Arthritis Res Ther (2016) 18(1):247. doi: 10.1186/s13075-016-1121-z
Ma Y Hong F-F Yang S-L. Role of prostaglandins in rheumatoid arthritis. Clin Exp Rheumatol (2021) 39(1):162–725. doi: 10.55563/clinexprheumatol/1jlh15
Angiolilli C Kabala PA Grabiec AM Rossato M Lai W Fossati G et al. Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation. Arthritis Res Ther (2018) 20(1):148. doi: 10.1186/s13075-018-1638-4
Karonitsch T Kandasamy RK Kartnig F Herdy B Dalwigk K Niederreiter B et al. mTOR senses environmental cues to shape the fibroblast-like synoviocyte response to inflammation. Cell Rep (2018) 23(7):2157–67. doi: 10.1016/j.celrep.2018.04.044
Jin U-H Lee S-O Sridharan G Lee K Davidson LA Jayaraman A et al. Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. Mol Pharmacol (2014) 85(5):777–885. doi: 10.1124/mol.113.091165
Stengel ST Fazio A Lipinski S Jahn MT Aden K Ito Go et al. Activating transcription factor 6 mediates inflammatory signals in intestinal epithelial cells upon endoplasmic reticulum stress. Gastroenterology (2020) 159(4):1357–1374.e10. doi: 10.1053/j.gastro.2020.06.088
Bulek K Zhao J Liao Y Rana N Corridoni D Antanaviciute A et al. Epithelial-derived gasdermin D mediates nonlytic IL-1β Release during experimental colitis. J Clin Invest (2020) 130(8):4218–34. doi: 10.1172/JCI138103
Ushio A Arakaki R Yamada A Saito M Tsunematsu T Kudo Y et al. Crucial roles of macrophages in the pathogenesis of autoimmune disease. World J Immunol (2017) 7(1):15. doi: 10.5411/wji.v7.i1.1
Fu X Liu H Huang G Dai S-S. The emerging role of neutrophils in autoimmune-associated disorders: effector, predictor, and therapeutic targets. MedComm (2021) 2(3):402–135. doi: 10.1002/mco2.69
Chang LH Huang HS Wu PT Jou IM Pan MH Chang WC et al. Role of macrophage CCAAT/enhancer binding protein delta in the pathogenesis of rheumatoid arthritis in collagen-induced arthritic mice. PloS One (2012) 7(9):e45378. doi: 10.1371/journal.pone.0045378
Xu J Jiang C Wang X Geng M Peng Y Guo Y et al. Upregulated PKM2 in macrophages exacerbates experimental arthritis via STAT1 signaling. J Immunol (2020) 205(1):181–92. doi: 10.4049/jimmunol.1901021
Heiden V Matthew G Locasale JW Swanson KD Sharfi H Heffron GJ et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Sci (New York N.Y.) (2010) 329(5998):1492–99. doi: 10.1126/science.1188015
Tsai F Homan PJ Agrawal H Misharin AV Abdala-Valencia H Haines GK et al. Bim suppresses the development of SLE by limiting myeloid inflammatory responses. J Exp Med (2017) 214(12):3753–73. doi: 10.1084/jem.20170479
Jefferies CA. Regulating IRFs in IFN driven disease. Front Immunol (2019) 10:325(March). doi: 10.3389/fimmu.2019.00325
Lin EY-H Lai H-J Cheng Y-K Leong K-Q Cheng L-C Chou Y-C et al. Neutrophil extracellular traps impair intestinal barrier function during experimental colitis. Biomedicines (2020) 8(8):2755. doi: 10.3390/biomedicines8080275
Zhang T Mei Y Dong W Wang J Huang F Wu J. Evaluation of protein arginine deiminase-4 inhibitor in TNBS- induced colitis in mice. Int Immunopharmacol (2020) 84(July):106583. doi: 10.1016/j.intimp.2020.106583
Barbara G Barbaro MR Fuschi D Palombo M Falangone F Cremon C et al. Inflammatory and microbiota-related regulation of the intestinal epithelial barrier. Front Nutr (2021) 8:718356(September). doi: 10.3389/fnut.2021.718356
Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol (2021) 21(11):739–51. doi: 10.1038/s41577-021-00538-7
Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci (2013) 70(4):631–59. doi: 10.1007/s00018-012-1070-x
Olivares-Villagómez D Kaer LV. Intestinal intraepithelial lymphocytes: sentinels of the mucosal barrier. Trends Immunol (2018) 39(4):264–755. doi: 10.1016/j.it.2017.11.003
Rivas MA Beaudoin Mélissa Gardet A Stevens C Sharma Y Zhang CK et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet (2011) 43(11):1066–73. doi: 10.1038/ng.952
Mohanan V Nakata T Nicole Desch A Lévesque Chloé Boroughs A Guzman G et al. C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions. Sci (New York N.Y.) (2018) 359(6380):1161–66. doi: 10.1126/science.aan0814
Aden K Tran F Ito G Sheibani-Tezerji R Lipinski S Kuipe JW et al. ATG16L1 orchestrates interleukin-22 signaling in the intestinal epithelium via cGAS-STING. J Exp Med (2018) 215(11):2868–86. doi: 10.1084/jem.20171029
Zhang X Zhang D Jia H Feng Q Wang D Liang Di et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med (2015) 21(8):895–905. doi: 10.1038/nm.3914
Alshehri D Saadah O Mosli M Edris S Alhindi R Bahieldin A. Dysbiosis of gut microbiota in inflammatory bowel disease: current therapies and potential for microbiota-Modulating therapeutic approaches. Bosnian J Basic Med Sci (2020) 21:270–83. doi: 10.17305/bjbms.2020.5016
Tomofuji Y Maeda Y Oguro-Igashira E Kishikawa T Yamamoto K Sonehara K et al. Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese. Ann Rheumatic Dis (2021) 80(12):1575–83. doi: 10.1136/annrheumdis-2021-220687
Forbes JD Domselaar GV Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol (2016) 7:1081(July). doi: 10.3389/fmicb.2016.01081
Rojas M Restrepo-Jiménez P Monsalve DM Pacheco Y Acosta-Ampudia Y Ramírez-Santana C et al. Molecular mimicry and autoimmunity. J Autoimmun (2018) 95(December):100–23. doi: 10.1016/j.jaut.2018.10.012
Zhang P Lu Q. Genetic and epigenetic influences on the loss of tolerance in autoimmunity. Cell Mol Immunol (2018) 15(6):575–855. doi: 10.1038/cmi.2017.137
Joo H Coquery C Xue Y Gayet I Dillon SR Punaro M et al. Serum from patients with SLE instructs monocytes to promote igG and igA plasmablast differentiation. J Exp Med (2012) 209(7):1335–485. doi: 10.1084/jem.20111644
Caielli S Veiga DT Balasubramanian P Athale S Domic B Murat E et al. A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. Nat Med (2019) 25(1):75–81. doi: 10.1038/s41591-018-0254-9
Teichmann LL Schenten D Medzhitov R Kashgarian M Shlomchik MJ. Signals via the adaptor myD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity (2013) 38(3):528–405. doi: 10.1016/j.immuni.2012.11.017
Kim CJ Lee C-G Jung J-Y Ghosh A Hasan SN Hwang S-M et al. The transcription factor ets1 suppresses T follicular helper type 2 cell differentiation to halt the onset of systemic lupus erythematosus. Immunity (2018) 49(6):1034–1048.e8. doi: 10.1016/j.immuni.2018.10.012
Klein U Casola S Cattoretti G Shen Q Lia M Mo T et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol (2006) 7(7):773–825. doi: 10.1038/ni1357
Jacquemin Clément Augusto Jean-François Scherlinger M Gensous Noémie Forcade E Douchet I et al. OX40L/OX40 axis impairs follicular and natural treg function in human SLE. JCI Insight (2018) 3(24):122167. doi: 10.1172/jci.insight.122167
Jenks SA Cashman KS Zumaquero E Marigorta UM Patel AV Wang X et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity (2018) 49(4):725–739.e6. doi: 10.1016/j.immuni.2018.08.015
Bennike TB Ellingsen T Glerup H Bonderup OK Carlsen TG Meyer MK et al. Proteome analysis of rheumatoid arthritis gut mucosa. J Proteome Res (2017) 16(1):346–54. doi: 10.1021/acs.jproteome.6b00598
Catrina A Krishnamurthy A Rethi B. Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis. RMD Open (2021) 7(1):e0012285. doi: 10.1136/rmdopen-2020-001228
Scally SW Petersen J Law SC Dudek NL Nel HJ Loh KL et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med (2013) 210(12):2569–82. doi: 10.1084/jem.20131241
Ito Y Hashimoto M Hirota K Ohkura N Morikawa H Nishikawa H et al. Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Sci (New York N.Y.) (2014) 346(6207):363–68. doi: 10.1126/science.1259077
Kuhn KA Kulik L Tomooka B Braschler KJ Arend WP Robinson WH et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest (2006) 116(4):961–735. doi: 10.1172/JCI25422
Hill JA Bell DA Brintnell W Yue D Wehrli B Jevnikar AM et al. Arthritis induced by posttranslationally modified (Citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med (2008) 205(4):967–795. doi: 10.1084/jem.20072051
Harre U Georgess D Bang H Bozec A Axmann R Ossipova E et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 122(5):1791–802. doi: 10.1172/JCI60975
Zhou X Motta F Selmi C Ridgway WM Gershwin ME Zhang W. Antibody glycosylation in autoimmune diseases. Autoimmun Rev (2021) 20(5):1028045. doi: 10.1016/j.autrev.2021.102804
Pfeifle René Rothe T Ipseiz N Scherer HU Culemann S Harre U et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol (2017) 18(1):104–13. doi: 10.1038/ni.3579
Chen ML Sundrud MS. Cytokine networks and T-cell subsets in inflammatory bowel diseases. Inflamm Bowel Dis (2016) 22(5):1157–675. doi: 10.1097/MIB.0000000000000714
Casalegno Garduño R Däbritz J. New insights on CD8+ T cells in inflammatory bowel disease and therapeutic approaches. Front Immunol (2021) 12:738762(October). doi: 10.3389/fimmu.2021.738762
Gomez-Bris R Saez A Herrero-Fernandez B Rius C Sanchez-Martinez H Gonzalez-Granado JM. CD4 T-cell subsets and the pathophysiology of inflammatory bowel disease. Int J Mol Sci (2023) 24(3):26965. doi: 10.3390/ijms24032696
Malmström V Catrina AI Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol (2017) 17(1):60–755. doi: 10.1038/nri.2016.124
Tenbrock K Rauen T. T cell dysregulation in SLE. Clin Immunol (2022) 239(June):109031. doi: 10.1016/j.clim.2022.109031
Chen P-M Tsokos GC. The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update. Curr Opin Rheumatol (2021) 33(6):586–915. doi: 10.1097/BOR.0000000000000815
Wiede F Shields BJ Chew SH Kyparissoudis K Vliet Cv Galic S et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J Clin Invest (2011) 121(12):4758–745. doi: 10.1172/JCI59492
Faliti CE Gualtierotti R Rottoli E Gerosa M Perruzza L Romagnani A et al. P2X7 receptor restrains pathogenic tfh cell generation in systemic lupus erythematosus. J Exp Med (2019) 216(2):317–36. doi: 10.1084/jem.20171976
Sjaastad LE Owen DL Tracy SI Farrar MA. Phenotypic and functional diversity in regulatory T cells. Front Cell Dev Biol (2021) 9:715901. doi: 10.3389/fcell.2021.715901
Catalán D Mansilla MAndrés Ferrier A Soto L Oleinika K Aguillón JC et al. Immunosuppressive mechanisms of regulatory B cells. Front Immunol (2021) 12:611795(April). doi: 10.3389/fimmu.2021.611795
Dasgupta S Dasgupta S Bandyopadhyay M. Regulatory B cells in infection, inflammation, and autoimmunity. Cell Immunol (2020) 352(June):104076. doi: 10.1016/j.cellimm.2020.104076
Sakaguchi S Mikami N Wing JB Tanaka A Ichiyama K Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol (2020) 38(1):541–665. doi: 10.1146/annurev-immunol-042718-041717
Nie H Zheng Y Li R Guo TB He D Fang L et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med (2013) 19(3):322–28. doi: 10.1038/nm.3085
Singh UP Singh NP Guan H Busbee B Price RL Taub DD et al. Leptin antagonist ameliorates chronic colitis in IL-10–/– mice. Immunobiology (2013) 218(12):1439–515. doi: 10.1016/j.imbio.2013.04.020
Rauber S Luber M Weber S Maul L Soare A Wohlfahrt T et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat Med (2017) 23(8):938–44. doi: 10.1038/nm.4373
Ding Y Li J Yang P Luo B Wu Qi Zajac AJ et al. Interleukin-21 promotes germinal center reaction by skewing the follicular regulatory T cell to follicular helper T cell balance in autoimmune BXD2 mice. Arthritis Rheumatol (Hoboken N.J.) (2014) 66(9):2601–125. doi: 10.1002/art.38735
Wang CJ Heuts F Ovcinnikovs V Wardzinski L Bowers C Schmidt EM et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci USA (2015) 112(2):524–295. doi: 10.1073/pnas.1414576112
Jandl C Liu SM Cañete PF Warren J Hughes WE Vogelzang A et al. IL-21 restricts T follicular regulatory T cell proliferation through bcl-6 mediated inhibition of responsiveness to IL-2. Nat Commun (2017) 8(March):14647. doi: 10.1038/ncomms14647
Svensson MNd Doody KM Schmiedel BJ Bhattacharyya S Panwar B Wiede F et al. Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of tregs in autoimmunity. J Clin Invest (2019) 129(3):1193–210. doi: 10.1172/JCI123267
Zeissig S Rosati E Marie Dowds C Aden K Bethge J Schulte B et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut (2019) 68(1):25–39. doi: 10.1136/gutjnl-2018-316023
Ren B Liu J Wu K Zhang J Lv Y Wang S et al. TNF-α-elicited miR-29b potentiates resistance to apoptosis in peripheral blood monocytes from patients with rheumatoid arthritis. Apoptosis (2019) 24(11-12):892–904. doi: 10.1007/s10495-019-01567-3
Derer S Till A Haesler R Sina C Grabe N Jung S et al. mTNF reverse signalling induced by TNFα Antagonists involves a GDF-1 dependent pathway: implications for crohn’s disease. Gut (2013) 62(3):376–86. doi: 10.1136/gutjnl-2011-300384
Picardo S So K Venugopal K. Anti-TNF-induced lupus in patients with inflammatory bowel disease. JGH Open (2019) 4(3):507–10. doi: 10.1002/jgh3.12291
Andres-Ejarque R Ale HB Grys K Tosi I Solanky S Ainali C et al. Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nat Commun (2021) 12(1):4741. doi: 10.1038/s41467-021-25066-9
Tréton X Pedruzzi E Guichard Cécile Ladeiro Y Sedghi S Vallée Mélissa et al. Combined NADPH oxidase 1 and interleukin 10 deficiency induces chronic endoplasmic reticulum stress and causes ulcerative colitis-like disease in mice. PloS One (2014) 9(7):e101669. doi: 10.1371/journal.pone.0101669
Xu Mo Pokrovskii M Ding Yi Yi R Au C Harrison OJ et al. C-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature (2018) 554(7692):373–77. doi: 10.1038/nature25500
Ni S Shan F Geng J. Interleukin-10 family members: biology and role in the bone and joint diseases. Int Immunopharmacol (2022) 108(July):108881. doi: 10.1016/j.intimp.2022.108881
Okada Y Muramatsu T Suita N Kanai M Kawakami E Iotchkova V et al. Significant impact of miRNA–target gene networks on genetics of human complex traits. Sci Rep (2016) 6(1):222235. doi: 10.1038/srep22223
van Baarsen LGm Wijbrandts CA Rustenburg François Cantaert T Kraan TCvd Baeten DL et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther (2010) 12(1):R11. doi: 10.1186/ar2912
Clément Jean-François Bibeau-Poirier A Gravel S-P Grandvaux N Bonneil Éric Thibault P et al. Phosphorylation of IRF-3 on ser 339 generates a hyperactive form of IRF-3 through regulation of dimerization and CBP association. J Virol (2008) 82(8):3984–965. doi: 10.1128/JVI.02526-07
Mazein A Ostaszewski M Kuperstein I Watterson S Novère NLe Lefaudeux D et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms. NPJ Syst Biol Appl (2018) 4:21. doi: 10.1038/s41540-018-0059-y
Nam Y Jhee JHo Cho J Lee J-H Shin H. Disease gene identification based on generic and disease-specific genome networks. Bioinformatics (2019) 35(11):1923–305. doi: 10.1093/bioinformatics/bty882
Zhang Q Sun L Zhang Q Zhang W Tian W Liu M et al. Construction of a disease-specific lncRNA-miRNA-mRNA regulatory network reveals potential regulatory axes and prognostic biomarkers for hepatocellular carcinoma. Cancer Med (2020) 9(24):9219–355. doi: 10.1002/cam4.3526
Ruan P Wang S. DiSNEP: A disease-specific gene network enhancement to improve prioritizing candidate disease genes. Briefings Bioinf (2021) 22(4):bbaa241. doi: 10.1093/bib/bbaa241
Gomez M Cristobal L Kondratova M Ravel J-M Barillot E Zinovyev A et al. Application of atlas of cancer signalling network in preclinical studies. Briefings Bioinf (2019) 20(2):701–165. doi: 10.1093/bib/bby031
Miagoux Q Singh V Mézquita Dde Chaudru V Elati M Petit-Teixeira E et al. Inference of an integrative, executable network for rheumatoid arthritis combining data-Driven machine learning approaches and a state-of-the-Art mechanistic disease map. J Personalized Med (2021) 11(8):7855. doi: 10.3390/jpm11080785
Hoch M Smita S Cesnulevicius K Lescheid D Schultz M Wolkenhauer O et al. Network- and enrichment-based inference of phenotypes and targets from large-scale disease maps. NPJ Syst Biol Appl (2022) 8(1):135. doi: 10.1038/s41540-022-00222-z
